According to Nashville-based Neoplas Innovation, the first mesothelioma patient to be treated with its new treatment protocol has responded favorably. The mesothelioma treatment protocol, which has been tested on a number of other aggressive cancers, involves a combination of low-dose interferon and lovastatin.
This initial test patient was not been helped by standard mesothelioma treatments. And although her response to the new treatment has been favorable, the response of a single patient is not enough information to draw any conclusions about the treatment’s clinical effectiveness.
The two drugs that are being used in the mesothelioma treatment protocol are existing drugs being used in a new, “off-label” way. Lovastatin is generally used to lower cholesterol. More than ten years ago, lovastatin was shown to attack mesothelioma cells in lab cultures.
NeoPlas Innovation’s Press Release.- All Press Releases for May 14, 2009
After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well.
The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising.
Nashville, Tenn. (Vocus/PRWEB ) May 14, 2009 -- After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
The first mesothelioma patient is a woman in her late forties who was exposed to asbestos in childhood. When her cancer was diagnosed in 2008, it already had filled most of the chest space where her right lung had been. She received the approved treatments for the cancer. As is typical for mesothelioma, however, it continued to grow steadily. Realizing that the usual chemotherapy regimen is never able to stop this cancer, she visited NeoPlas Innovation's Nashville clinic and began the new outpatient treatment.
Two months later, CT scans showed that the cancer had stabilized, and the largest of the tumors actually had regressed significantly in size. Improvement in her clinical condition correlated with the findings. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma and certain sarcomas. It can be considered for other patients on a case-by-case basis.
The new treatment is simply an "off-label" combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. In 1998 Dr. Jeffrey Rubins and colleagues in Minneapolis demonstrated that lovastatin had a significant effect against mesothelioma cells in laboratory cultures. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, patients have experienced active regression of tumors.
Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.
NeoPlas Innovation's web site, www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.
For an interview with Dr. Cantrell, call 615-371-8100.
This initial test patient was not been helped by standard mesothelioma treatments. And although her response to the new treatment has been favorable, the response of a single patient is not enough information to draw any conclusions about the treatment’s clinical effectiveness.
The two drugs that are being used in the mesothelioma treatment protocol are existing drugs being used in a new, “off-label” way. Lovastatin is generally used to lower cholesterol. More than ten years ago, lovastatin was shown to attack mesothelioma cells in lab cultures.
NeoPlas Innovation’s Press Release.- All Press Releases for May 14, 2009
After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well.
The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising.
Nashville, Tenn. (Vocus/PRWEB ) May 14, 2009 -- After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
The first mesothelioma patient is a woman in her late forties who was exposed to asbestos in childhood. When her cancer was diagnosed in 2008, it already had filled most of the chest space where her right lung had been. She received the approved treatments for the cancer. As is typical for mesothelioma, however, it continued to grow steadily. Realizing that the usual chemotherapy regimen is never able to stop this cancer, she visited NeoPlas Innovation's Nashville clinic and began the new outpatient treatment.
Two months later, CT scans showed that the cancer had stabilized, and the largest of the tumors actually had regressed significantly in size. Improvement in her clinical condition correlated with the findings. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma and certain sarcomas. It can be considered for other patients on a case-by-case basis.
The new treatment is simply an "off-label" combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. In 1998 Dr. Jeffrey Rubins and colleagues in Minneapolis demonstrated that lovastatin had a significant effect against mesothelioma cells in laboratory cultures. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, patients have experienced active regression of tumors.
Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.
NeoPlas Innovation's web site, www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.
For an interview with Dr. Cantrell, call 615-371-8100.
1 comments:
Here is a great chance to drive a large number of visitors to your blogs and websites for free.
Submit your websites, blogs, videos to http://www.zillionsb.com and get 1000s of targeted visitors everyday for free. It also helps your websites/blogs gain valuable backlinks.
Let the other bloggers cast their votes to push your posts up for a greater visibility. Enjoy a free, huge traffic to your sites.
Thanks
Sara
http://www.zillionsb.com
Post a Comment
First Mesothelioma Success treatment
This initial test patient was not been helped by standard mesothelioma treatments. And although her response to the new treatment has been favorable, the response of a single patient is not enough information to draw any conclusions about the treatment’s clinical effectiveness.
The two drugs that are being used in the mesothelioma treatment protocol are existing drugs being used in a new, “off-label” way. Lovastatin is generally used to lower cholesterol. More than ten years ago, lovastatin was shown to attack mesothelioma cells in lab cultures.
NeoPlas Innovation’s Press Release.- All Press Releases for May 14, 2009
After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well.
The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising.
Nashville, Tenn. (Vocus/PRWEB ) May 14, 2009 -- After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.
The first mesothelioma patient is a woman in her late forties who was exposed to asbestos in childhood. When her cancer was diagnosed in 2008, it already had filled most of the chest space where her right lung had been. She received the approved treatments for the cancer. As is typical for mesothelioma, however, it continued to grow steadily. Realizing that the usual chemotherapy regimen is never able to stop this cancer, she visited NeoPlas Innovation's Nashville clinic and began the new outpatient treatment.
Two months later, CT scans showed that the cancer had stabilized, and the largest of the tumors actually had regressed significantly in size. Improvement in her clinical condition correlated with the findings. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma and certain sarcomas. It can be considered for other patients on a case-by-case basis.
The new treatment is simply an "off-label" combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. In 1998 Dr. Jeffrey Rubins and colleagues in Minneapolis demonstrated that lovastatin had a significant effect against mesothelioma cells in laboratory cultures. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, patients have experienced active regression of tumors.
Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.
NeoPlas Innovation's web site, www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.
For an interview with Dr. Cantrell, call 615-371-8100.
Labels: mesothelioma, mesothelioma news, mesothelioma treatments